Market Overview

UPDATE: Oppenheimer Raises PT on Celldex Therapeutics on Key Clinical Milestones, Associated Trials Anticipated In 2H13

Share:
Related CLDX
US Stock Futures Signal Higher Start On Wall Street
Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co. (Seeking Alpha)

In a report published on Friday, Oppenheimer analyst Boris Peaker raised the price target on Celldex Therapeutics (NASDAQ: CLDX) from $14 to $16 and reiterated a rating of Outperform on the company.

In the report, Oppenheimer stated, "We believe that investors will be focused on the Rindo studies in brain cancer as well as initial data for CDX-1135 and CDX-1127. Additionally, we performed further due diligence on CDX-1135 and we are adding this compound to our valuation. This is the basis for our price target increase of $2/share (from $14 to $16)."

Celldex Therapeutics closed on Thursday at $14.29.

Latest Ratings for CLDX

DateFirmActionFromTo
Mar 2015JefferiesMaintainsBuy
Mar 2015Cantor FitzgeraldMaintainsBuy
Sep 2014Cowen & CompanyInitiates Coverage onOutperform

View More Analyst Ratings for CLDX
View the Latest Analyst Ratings

Posted-In: Boris Peaker OppenheimerAnalyst Color Price Target Analyst Ratings

 

Related Articles (CLDX)

Around the Web, We're Loving...